Vildagliptin

Generic Name
Vildagliptin
Brand Names
Galvus, Jalra, Xiliarx
Drug Type
Small Molecule
Chemical Formula
C17H25N3O2
CAS Number
274901-16-5
Unique Ingredient Identifier
I6B4B2U96P
Background

Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired. By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependen...

Indication

Vildagliptin is indicated in the treatment of type II diabetes mellitus in adults. As monotherapy, vildagliptin is indicated in adults inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. It is also indicated as dual therapy in combination with metformin, a sulphonylurea, or a thi...

Associated Conditions
Type 2 Diabetes Mellitus
Associated Therapies
-
Clinical Trials
Related News

Evaluation of Continuous Glucose Monitoring in Participants With Type 2 Diabetes Mellitus (MK-0000-258 AM2)

Phase 1
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Vildagliptin
Drug: Placebo
First Posted Date
2012-02-23
Last Posted Date
2015-08-19
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
25
Registration Number
NCT01537120

VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus

First Posted Date
2012-02-07
Last Posted Date
2020-09-24
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
2004
Registration Number
NCT01528254
Locations
🇹🇷

Novartis Investigative Site, Kahramanmaras, Turkey

Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: Vildagliptin
Drug: Placebo
First Posted Date
2011-12-22
Last Posted Date
2017-02-27
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
183
Registration Number
NCT01497522
Locations
🇯🇵

Novartis Investigative Site, Kyoto, Japan

DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes

Phase 4
Completed
Conditions
Chronic Foot Ulcers
Interventions
Drug: Placebo
Drug: vildagliptin
First Posted Date
2011-11-16
Last Posted Date
2016-10-11
Lead Sponsor
University of Campania "Luigi Vanvitelli"
Target Recruit Count
106
Registration Number
NCT01472432
Locations
🇮🇹

Second university of Naples, Naples, Italy

Effect of Autonomic Neuropathy on the Efficacy of a DPP-IV Inhibitor (Galvus) Therapy

Phase 2
Completed
Conditions
Diabetes Mellitus
Interventions
Drug: Vildagliptin
First Posted Date
2011-10-14
Last Posted Date
2014-03-12
Lead Sponsor
University Hospital, Toulouse
Target Recruit Count
21
Registration Number
NCT01452113
Locations
🇫🇷

UH Toulouse, Toulouse, France

The Swiss Glucose Variability Study

Phase 4
Conditions
Type 2 Diabetes
First Posted Date
2011-08-31
Last Posted Date
2011-08-31
Lead Sponsor
University of Zurich
Target Recruit Count
50
Registration Number
NCT01426737
Locations
🇨🇭

Universitiy Hospital, Zurich, Switzerland

Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

Phase 4
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: vildagliptin
First Posted Date
2011-08-31
Last Posted Date
2017-02-27
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
150
Registration Number
NCT01426802
Locations
🇪🇬

Investigative site, Cairo, Egypt

Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy

First Posted Date
2011-07-20
Last Posted Date
2013-02-12
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
187
Registration Number
NCT01398592
Locations
🇩🇪

Novartis Investigative Site, Stuttgart, Germany

Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes

Phase 3
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Placebo
Drug: vildagliptin
First Posted Date
2011-05-20
Last Posted Date
2014-04-03
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
279
Registration Number
NCT01357252
Locations
🇨🇳

Novartis Investigative Site, Shanghai, China

Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin in Patients With Type 2 Diabetes

Phase 4
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Placebo
Drug: Vildagliptin
First Posted Date
2011-05-19
Last Posted Date
2013-08-30
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
43
Registration Number
NCT01356381
Locations
🇬🇧

Novartis Investigative Site, Newcastle Upon Tyne, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy